Patent US4245832A successfully refreshed from Google Patents.
Patent US5047227A successfully refreshed from Google Patents.
US5047227A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel and improved antibodies for site specific attachment of compounds
Assignee: Cytogen Corp
•
Filing: 1991-02-04
•
Granted: 1991-09-10
•
Expires: 2011-02-04
Abstract
Abstract Novel and improved antibody compositions comprising an antibody or antibody fragment having an increased number of sites on a carbohydrate side chain available for the site specific attachment of a compound to a region of the antibody or antibody fragment which is not part of nor directly involved with the antigen binding site are disclosed. Conjugates, prepared using the high-mannose-containing antibodies, which are characterized by substantially the same immunospecificity as the unmodified unconjugated antibody molecule, are also disclosed. The antibody compositions are advantageously used for a wide variety of therapeutic and diagnostic applications in both in vivo and in vitro targeted delivery systems and assays. Methods for preparing the antibody compositions, as well as antibody conjugate intermediates, and methods for using the antibody compositions are also described.
Inventors
- 👤 John D. Rodwell
- 👤 Thomas J. McKearn
- 👤 Cynthia G. Long
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 08:27
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1093; A61K51/1045; A61K2121/00; A61K2123/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
120 words
A method for treating a cellular disorder, comprising: administering to an animal or a human a therapeutically effective amount of an aqueous soluble antibody-compound conjugate which comprises a compound attached via a covalent bond to an oxidized carbohydrate moiety of a high-mannose containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment and which is immunoreactive with and immunospecific for a target site associated with the cellular disorder and substantially non-immunoreactive with and non-immunospecific for tissue not associated with the cellular disorder.
Claim 2
Independent Claim
120 words
A method for treating a cellular disorder, comprising: administering to an animal or a human a therapeutically effective amount of an aqueous soluble antibody-compound conjugate which comprises a compound attached via a covalent bond to an oxidized carbohydrate moiety of a high-mannose containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment and which is immunoreactive with and immunospecific for a target site associated with the cellular disorder and substantially non-immunoreactive with and non-immunospecific for tissue not associated with the cellular disorder.
Claim 3
Independent Claim
132 words
A method for treating a cellular disorder, comprising: adminstering to an animal or a human a therapeutically effective amount of an aqueous soluble antibody-linker compound conjugate which comprises a compound attached either covalently or coordinately to a linker which is attached via a covalent bond to an oxidized carbohydrate moeity of a high mannose-containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-linker compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment and which is immunoreactive with and immunospecific for a target site associated with the cellular disorder and substantially non-immunoreactive with and non-immunospecific for tissue not associated with the cellular disorder.
Claim 4
Independent Claim
132 words
A method for treating a cellular disorder, comprising: adminstering to an animal or a human a therapeutically effective amount of an aqueous soluble antibody-linker compound conjugate which comprises a compound attached either covalently or coordinately to a linker which is attached via a covalent bond to an oxidized carbohydrate moeity of a high mannose-containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-linker compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment and which is immunoreactive with and immunospecific for a target site associated with the cellular disorder and substantially non-immunoreactive with and non-immunospecific for tissue not associated with the cellular disorder.
Claim 5
Independent Claim
127 words
A method for in vivo imaging a specific tissue comprising; (a) administering to an animal or a human an effective amount of an antibody-compound conjugate which comprises a compound attached via a covalent bond to an oxidized carbohydrate moiety of a high-mannose containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment which is immunoreactive with and immunospecific for an antigenic determinant of the specific tissue and is not found in substantial amount in non-specific tissue; and (b) detecting whether the antibody compound conjugate localized at the specific tissue.
Claim 6
Independent Claim
127 words
A method for in vivo imaging a specific tissue comprising; (a) administering to an animal or a human an effective amount of an antibody-compound conjugate which comprises a compound attached via a covalent bond to an oxidized carbohydrate moiety of a high-mannose containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment which is immunoreactive with and immunospecific for an antigenic determinant of the specific tissue and is not found in substantial amount in non-specific tissue; and (b) detecting whether the antibody compound conjugate localized at the specific tissue.
Claim 7
Independent Claim
139 words
A method for in vivo imaging a specific tissue comprising: (a) administering to an animal or a human an effective amount of an antibody-linker compound conjugate which comprises a compound attached either covalently or coordinately to a linker which is attached via a covalent bond to an oxidized carbohydrate moeity of a high mannose-containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-linker compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment which is immunoreactive with and immunospecific for an antigenic determinant of the specific tissue and is not found in substantial amount in non-specific tissue; and (b) detecting whether the antibody-linker compound conjugate localized at the specific tissue.
Claim 8
Independent Claim
139 words
A method for in vivo imaging a specific tissue comprising: (a) administering to an animal or a human an effective amount of an antibody-linker compound conjugate which comprises a compound attached either covalently or coordinately to a linker which is attached via a covalent bond to an oxidized carbohydrate moeity of a high mannose-containing antibody or antibody fragment, in which the oxidized carbohydrate moiety is not part of nor directly involved with the antigen binding site of the antibody or antibody fragment, to form an antibody-linker compound conjugate being characterized by substantially the same immunospecificity as the unconjugated antibody or antibody fragment which is immunoreactive with and immunospecific for an antigenic determinant of the specific tissue and is not found in substantial amount in non-specific tissue; and (b) detecting whether the antibody-linker compound conjugate localized at the specific tissue.
Claim 9
Dependent Claim
18 words
The method of claim 1, in which the compound is an amine containing derivative of an anthracycline antibiotic.
Claim 10
Dependent Claim
16 words
The method of claim 1, in which the compound is an amine containing derivative of cisplatin.
Claim 11
Dependent Claim
31 words
The method of claim 1, in which the compound is an amine containing derivative of a compound selected from the group consisting of fluorouracil, bleomycin, methotrexate, aminopterin, adriamycin, velban and alkeran.
Claim 12
Dependent Claim
18 words
The method of claim 1, in which the compound is an antibacterial, antiviral, antifungal, antiparasitic or antimycoplasmal agent.
Claim 13
Dependent Claim
28 words
The method of claim 1, in which the compound is selected from the group consisting of a radioactive isotope, a non-metallic radioactive isotope and a radioactive metal ion.
Claim 14
Dependent Claim
18 words
The method of claim 2, in which the compound is an amine containing derivative of an anthracycline antibiotic.
Claim 15
Dependent Claim
16 words
The method of claim 2, in which the compound is an amine containing derivative of cisplatin.
Claim 16
Dependent Claim
31 words
The method of claim 2, in which the compound is an amine containing derivative of a compound selected from the group consisting of fluoruracil, bleomycin, methotrexate, aminopterin, adriamycin, velban and alkeran.
Claim 17
Dependent Claim
18 words
The method of claim 2, in which the compound is an antibacterial, antiviral, antifungal, antiparasitic or antimycoplasmal agent.
Claim 18
Dependent Claim
28 words
The method of claim 2, in which the compound is selected from the group consisting of a radioactive isotope, a non-metallic radioactive isotope and a radioactive metal ion.
Claim 19
Dependent Claim
28 words
The method of claim 3, in which the compound is selected from the group consisting of a radioactive isotope, a non-metallic radioactive isotope and a radioactive metal ion.
Claim 20
Dependent Claim
28 words
The method of claim 4, in which the compound is selected from the group consisting of a radioactive isotope, a non-metallic radioactive isotope and a radioactive metal ion.
References Cited (Backward Citations)
US3447893A
Cited
US4217338A
Cited
US4419444A
Cited
US4671958A
Cited
US4634666A
Cited
EP0173629A1
Cited
EP0175617B1
Cited
US4699784A
Cited
US4925796A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-09 | 1995-03-11 | 1995-09-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-09 | 1999-03-11 | 1999-09-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-09 | 2003-03-11 | 2003-09-10 | $7700.00 | Window Closed / Lapsed |